- Home
- TLPH vs ERNA Comparison
TLPH vs ERNA Comparison
Compare TLPH & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- ERNA
- Stock Information
- Founded
- TLPH 2005
- ERNA 2018
- Country
- TLPH United States
- ERNA United States
- Employees
- TLPH N/A
- ERNA N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- ERNA Health Care
- Exchange
- TLPH Nasdaq
- ERNA Nasdaq
- Market Cap
- TLPH 11.1M
- ERNA 10.2M
- IPO Year
- TLPH 2011
- ERNA N/A
- Fundamental
- Price
- TLPH $0.79
- ERNA $1.22
- Analyst Decision
- TLPH Strong Buy
- ERNA
- Analyst Count
- TLPH 1
- ERNA 0
- Target Price
- TLPH $6.00
- ERNA N/A
- AVG Volume (30 Days)
- TLPH 3.4M
- ERNA 45.4K
- Earning Date
- TLPH 08-14-2025
- ERNA 08-13-2025
- Dividend Yield
- TLPH N/A
- ERNA N/A
- EPS Growth
- TLPH N/A
- ERNA N/A
- EPS
- TLPH N/A
- ERNA N/A
- Revenue
- TLPH $27,000.00
- ERNA $488,000.00
- Revenue This Year
- TLPH N/A
- ERNA N/A
- Revenue Next Year
- TLPH $14,533.26
- ERNA N/A
- P/E Ratio
- TLPH N/A
- ERNA N/A
- Revenue Growth
- TLPH N/A
- ERNA 201.24
- 52 Week Low
- TLPH $0.38
- ERNA $1.21
- 52 Week High
- TLPH $1.19
- ERNA $26.60
- Technical
- Relative Strength Index (RSI)
- TLPH 84.46
- ERNA 28.73
- Support Level
- TLPH $0.40
- ERNA $1.43
- Resistance Level
- TLPH $0.57
- ERNA $1.47
- Average True Range (ATR)
- TLPH 0.10
- ERNA 0.12
- MACD
- TLPH 0.02
- ERNA -0.01
- Stochastic Oscillator
- TLPH 56.72
- ERNA 2.44
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.